Clinical Trials at East Carolina University
As of September 2026, 78 paid clinical trials are recruiting at East Carolina University, located at 1001 EAST FIFTH STREET, GREENVILLE, NC 27858-4353, phone (252) 737-2821 in Greenville, North Carolina. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Sickle Cell Disease and Heart Failure. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Greenville
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
79 clinical trials at East Carolina University
·Clear filters·Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
PREnatal Choline and Infant Outcomes Study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Common conditions studied in Greenville
- Acute Myeloid Leukemia (9 active studies)
- Sickle Cell Disease (8 active studies)
- Heart Failure (4 active studies)
- Hypertension (4 active studies)
- Acute Myeloid Leukemia Post Cytotoxic Therapy (3 active studies)
- Atrial Fibrillation (3 active studies)
Leading research sponsors in Greenville
- National Cancer Institute (NCI)
- Children's Oncology Group
- East Carolina University
- Alliance for Clinical Trials in Oncology
- Pfizer
Frequently asked questions
How many paid clinical trials are currently recruiting in Greenville?
There are approximately 156 recruiting clinical trials in Greenville, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Greenville pay participants?
Most recruiting trials in Greenville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Greenville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Greenville?
The most common conditions under active study in Greenville include Acute Myeloid Leukemia (9), Sickle Cell Disease (8), Heart Failure (4), Hypertension (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Greenville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Greenville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Greenville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Greenville?
Recruiting research sites in Greenville include East Carolina University, Brody School of Medicine at East Carolina University, ECU Health Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Greenville right now?
The largest active categories in Greenville are Cancer & tumors (53), Cardiovascular (17), Diabetes & metabolic (7). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of East Carolina University?
East Carolina University is located at 1001 EAST FIFTH STREET, GREENVILLE, NC 27858-4353. Use the Google Maps link in the intro above to get directions.
How do I contact East Carolina University?
You can reach East Carolina University by phone at (252) 737-2821. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.